title: Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine.
abstract: A 64-year-old woman was admitted to our hospital for recurrent stroke and cognitive impairment and was diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Iodine-123 iodoamphetamine single photon emission computed tomography showed hypoperfusion in the whole brain, but cerebral blood flow increased dramatically after the administration of acetazolamide in the cerebral cortex. Lomerizine, a diphenylmethylpiperazine Ca2+ channel blocker, can selectively increase cerebral blood flow. Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients.
authors.affiliation: Department of Molecular Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan. mizuno@koto.kpu-m.ac.jp
authors.forename: Toshiki
authors.initials: T
authors.lastname: Mizuno
authors.forename: Masaki
authors.initials: M
authors.lastname: Kondo
authors.forename: Noriko
authors.initials: N
authors.lastname: Ishigami
authors.forename: Aiko
authors.initials: A
authors.lastname: Tamura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Itsukage
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Koizumi
authors.forename: Reina
authors.initials: R
authors.lastname: Isayama
authors.forename: Akiko
authors.initials: A
authors.lastname: Hosomi
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Nagakane
authors.forename: Takahiko
authors.initials: T
authors.lastname: Tokuda
authors.forename: Eizo
authors.initials: E
authors.lastname: Sugimoto
authors.forename: Yo
authors.initials: Y
authors.lastname: Ushijima
authors.forename: Masanori
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000661:Amphetamine; D046589:CADASIL / Q000150:complications* / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods; D018765:Dopamine Uptake Inhibitors; D005260:Female; D006801:Humans; D007456:Iodine Isotopes; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014055:Tomography, Emission-Computed / Q000379:methods; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods
chemical_list: D002121:Calcium Channel Blockers; D018765:Dopamine Uptake Inhibitors; D007456:Iodine Isotopes; D010879:Piperazines; D000661:Amphetamine; C052424:lomerizine